Merck and Co.‚ River Blindness Ethical Case Analysis Lennard de Jong Excelsior College Author Note This paper was prepared for Business Ethics‚ Ethical Case Analysis‚ taught by Dr. Moser. Introduction and Situational Analysis The ethical dilemma in Merck and River Blindness is whether to pursue research that may or may result in profit‚ or to choose the safe option and go for profit rather than researching the drug. The drug could possibly lead to curing the deadly and detrimental disease
Premium Ethics Morality
Pharmaceutical Industry The pharmaceutical industry includes companies that research‚ develop‚ market or distribute generic and branded drugs. The industry expanded during the 1980’s and drugs to treat heart disease and AIDS were prominent. Consumer demand for nutritional supplements and alternative medicine increased during the 1990’s with the Internet facilitating direct purchases of drugs. Advertising for direct consumption of pharmaceutical drugs became more prominent; pharmaceutical companies
Premium Inventory Pharmaceutical industry Dividend yield
Jim Mesplie MBA 519 – Competitive Strategy Case Analysis #4 FACTS Beginning as a small scale manufacturer of chemical in the United States‚ Merck Research Labs (MRL) became the top notch research institution in the pharmaceutical industry by World War II. By attracting the top talent in chemistry‚ biology‚ and pharmacology‚ MRL emerged as the leader in human pharmaceuticals with the release of highly necessary drugs to treat infections‚ and tuberculosis. MRL focused their strengths on three
Premium Generic drug Pharmacology Pharmaceutical industry
MAN 4720 Nov. 15‚ 2011 Merck‚ the FDA‚ and the Vioxx Recall In 1999 the Food and Drug Administration (FDA) had approved Vioxx‚ what would become Merck’s “blockbuster” drug. Although the FDA had approved the drug there was uncertainty of the safety of drug. Vioxx was approved to treat a variety of conditions‚ such as osteoarthritis and acute pain‚ but there was also a chance that it would increase cardiovascular problems. What I found most interesting about this case was the changes in how drugs
Premium Pharmacology Advertising Clinical trial
Merck‚ the FDA‚ and the VIOXX Recall MBA 520 Ethics and Leadership in a Global Environment 11.15.2009 MBA 520 15 November 2009 Merck‚ the FDA‚ and the VIOXX Recall In 1999‚ Merck started a clinical trial called VIGOR‚ checking the effectiveness of VIOXX in patients with gastrointestinal problems‚ and in this trial they noted for the first time that patients taking VIOXX suffered roughly twice as many heart attacks and strokes as those taking the control‚ Naproxen.
Premium Social responsibility Clinical trial Corporate social responsibility
Merck‚ the FDA‚ and the Vioxx Recall 1. Do you believe that Merck acted in a socially responsible and ethical manner with regard to Vioxx? Why or Why not? In your answer‚ please address the company’s drug development and testing‚ marketing and advertising‚ relationships with government regulators and policymakers‚ and handling of the recall. I do not believe that Merck made a socially responsible decision when Vioxx was introduced into the pharmaceutical market. Scientists that were involved
Premium Pharmacology
Merck and river blindness are a good example for Utilitarianism theory because the results brought happiness for both the company and the people. Utilitarianism is an ethical framework that focuses on the outcomes or results of actions. In fact‚ its name comes from the Greek word Telos‚ which means “end.” The two most influential developers of the utilitarian viewpoint were Englishmen Jeremy Bentham (1748–1832) and John Stuart Mill (1806–1873). Under this framework‚ acting ethically means making
Premium John Stuart Mill Ethics Jeremy Bentham
1) WHY? Brief Background on Merck & Co. Performance Appraisal System The past and existing performance appraisal of Merck & Co. was ineffective to identify and reward performance to a certain extent. Although the company was paying their employees around seven to eight percent more than the average compensation in other large companies‚ the performance appraisal system did not clearly identified outstanding performance‚ which caused inequity in rewarding performance and led to unhappiness
Premium Human resource management Performance Assessment
Guinea and Merck’s Gift to World: A Vaccine for Ebola Christmas may have come early to the West African nation of Guinea; a vaccine developed by Merck and tested on 4‚000 people in Guinea proved 100% effective. Sakoba Keita‚ Ebola response coordinator in Guinea called it Guinea’s gift to the world and it very well might be. Conditions of Testing There are certain medical concerns on the testing methodology. Due to the epidemic nature of the disease and the urgent need for a solution‚ no placebos
Premium Vaccination Vaccine Immune system
MERCK SHARPE & DOHME CASE SUMMARY QUESTIONS 1. Provide brief Background and Context In 1996 Merc Sharp & Dohme (MSD)‚ one of the top tier pharmaceutical firms in Argentina was undergoing fundamental changes in both its organizational structure as well as managerial philosophy. For over a year the company was under a new managing director who was leading the transformation of the company. The main goals at the time were to change the old hierarchical management system into a flatter
Premium Ethics Management